Compare Merck & Co., Inc. (MRK) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance

Merck & Co., Inc.Trade

Global X NASDAQ 100 Covered Call ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while Global X NASDAQ 100 Covered Call ETF trades at $17.81. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.

	MRK	QYLD
Market Cap	$307.25B	—
Sector	Health	Income / Options Overlay
52-Week High	$129.52	$18.52
52-Week Low	$77.60	$16.46
Enterprise Value	$350.66B	—
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Global X NASDAQ 100 Covered Call ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

QYLD

QYLD ETF's high yield masks risks; newer options ETFs offer safer income with better upside.24/7 Wall Street · 4 hours agoBearish Invesco's IQQQ ETF offers more Nasdaq upside than typical covered-call funds with daily call resets.24/7 Wall Street · 4 days agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Global X NASDAQ 100 Covered Call ETF

QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.